MYNZ Projected Dividend Yield
Ord/Mainz Biomed N V ( NASDAQ : MYNZ )Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. Co. operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. Co. competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc. 20 YEAR PERFORMANCE RESULTS |
MYNZ Dividend History Detail MYNZ Dividend News MYNZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |